Citigroup’s Enveric Biosciences ENVB Stock Holding History

Citigroup’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1	Buy	+1	New	+$1	﹤0.01%	5944
2026 Q1	–	Sell	-2,276	Closed	-$8.26K	–	6076
2025 Q4	$8.26K	Buy	+2,276	New	+$14.8K	﹤0.01%	5116
2022 Q2	–	Sell	-2	Closed	-$6K	–	6341
2022 Q1	$6K	Buy	+2	New	+$8.84K	﹤0.01%	5744

Other funds holding ENVB

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Citigroup's ENVB Position: Q3 2026 in Review

Citigroup opened a new position in Enveric Biosciences (ENVB) in Q3 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5944 among its holdings. This is a return to the name: Citigroup previously reported a position in ENVB as recently as Q4 2025.

Citigroup first reported a position in ENVB in Q1 2022 and has held it in 3 quarters since. The position peaked at $8.26K in Q4 2025. 6 funds tracked by Wall St. Rank hold ENVB as of Q3 2026.

Citigroup held 1 share of Enveric Biosciences worth $1 as of Q3 2026.
Enveric Biosciences was a new Citigroup position in Q3 2026.
Enveric Biosciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5944 holding.
Citigroup first reported a position in Enveric Biosciences in Q1 2022 and has held it in 3 quarters since.
Citigroup's Enveric Biosciences position peaked at $8.26K in Q4 2025.
6 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.